-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer

Benzinga·06/25/2026 12:10:44
Listen to the news

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead candidate, ateganosine, in advanced non-small cell lung cancer (NSCLC) patients receiving third line (3L) therapy. Ateganosine is an investigational dual-mechanism therapy targeting telomeres and immune activation in difficult-to-treat cancers.